GleamWall
中文EN

DTIL PRECISION BIOSCIENCES INC

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1357874 · Fiscal year ends 05/21

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY6,353.0%
TTM net income YoY53.9%
TTM EPS YoY103.6%
Revenue 3-yr CAGR-4.9%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-80.3%
Net margin-85.6%
FCF margin-115.0%
EBITDA margin-77.8%

Returns

ROE-112.7%
ROA-36.0%
ROIC (approx.)—
Asset turnover0.42x

Leverage & solvency

Liabilities / assets57.0%
Debt / equity0.00x
Current ratio10.47x
Interest coverage-28.56x

Cash quality & payout

Operating cash flow / net income1.34x
Accruals ratio12.4%
Payout ratio—
Capex / revenue0.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$0$0$10.84M$34.20M$13,000$18,000$29,000$638,000
R&D expense$12.74M$12.39M$13.11M$14.46M$13.35M$12.77M$13.59M$15.91M
SG&A expense$7.68M$6.77M$6.80M$7.23M$7.33M$9.13M$8.55M$9.58M
Operating income-$20.43M-$19.16M-$9.07M$12.51M-$20.67M-$21.88M-$22.11M-$24.85M
Interest expense$307,000$300,000$311,000$348,000$362,000$358,000$354,000$392,000
Net income-$7.59M-$32.65M-$18.44M$20.13M-$21.77M-$23.52M-$20.57M-$17.75M
EBITDA-$20.21M-$18.91M-$8.78M$12.85M-$20.32M-$21.50M-$21.72M-$24.39M
EPS (basic)-0.28-1.26-0.75—-1.84-2.13-2.21—
EPS (diluted)-0.28-1.26-0.75—-1.84-2.13-2.21—
Weighted avg. shares (diluted)27.43M25.86M24.63M—11.82M11.05M9.29M—
Balance sheet
Cash & equivalents$81.70M$86.08M$99.37M$110.82M$44.87M$62.24M$77.22M$108.47M
Short-term investments$148,000$1.47M$1.81M$4.76M$0$0—$413,000
Receivables$0$0$4.00M$0$4,000$0$4,000$229,000
Current assets$86.58M$91.55M$108.69M$118.74M$51.70M$70.26M$82.10M$94.99M
PP&E, net$779,000$964,000$1.18M$1.43M$2.03M$2.36M$2.72M$3.09M
Intangibles$1.06M$1.09M$1.13M$1.17M$985,000$605,000$607,000$622,000
Total assets$120.38M$125.92M$143.89M$154.42M$93.51M$108.93M$124.41M$136.39M
Current liabilities$8.27M$7.14M$7.75M$8.91M$15.00M$13.57M$12.39M$14.98M
Total liabilities$68.60M$80.63M$67.79M$62.17M$76.88M$74.87M$75.07M$80.00M
Shareholders' equity$51.77M$45.29M$76.10M$92.25M$16.63M$34.05M$49.34M$56.39M
Shares outstanding27.89M26.43M25.81M24.09M12.08M11.64M10.55M8.20M
Cash flow statement
Operating cash flow-$15.13M-$13.44M-$11.94M-$11.25M-$15.27M-$20.27M-$19.05M-$18.68M
Capital expenditure$0$0$18,000$19,000$0$2,000$64,000$97,000
Free cash flow-$15.13M-$13.44M-$11.96M-$11.27M-$15.27M-$20.27M-$19.12M-$18.78M
Investing cash flow-$200,000$1,000-$114,000-$325,000$17,000-$12,000-$314,000-$97,000
Financing cash flow$10.96M$0$745,000$77.52M$1.66M$5.30M$10.69M$5.92M
Depreciation & amortization$222,000$253,000$299,000$345,000$350,000$378,000$395,000$454,000
Stock-based compensation$2.96M$1.84M$1.55M$2.04M$2.39M$2.94M$2.82M$3.57M

Free plan shows the latest 8 periods; Pro shows all 35 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.